An Open-Label Extension of the Safety and Tolerability of Memantine in Pediatric Patients with Autism, Asperger Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

-
Investigator: Robert L. Hendren, DO
Sponsor: Forest Research Institute

Location(s): United States

Description

The objective of this study is to evaluate the long-term safety and tolerability of memantine in the treatment of pediatric patients with autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS). This clinical study will be a 48-week, multicenter, open-label extension study in pediatric outpatients with autism, Asperger's Disorder, or PDD-NOS conducted at approximately 180 study centers.